Simon AG, Esser LK, Ellinger J, Branchi V, Tolkach Y, Müller S, Ritter M, Kristiansen G, Muders MH, Mayr T, Toma MI (2020) J Cancer Res Clin Oncol. doi: 10.1007/s00432-020-03278-8 Borkowetz A, Froehner M, Rauner M, Conrad S, Erdmann K, Mayr T, Datta K, Hofbauer LC, Baretton GB, Wirth M, Fuessel S, Toma M*, Muders MH* (2019) Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. Int J Cancer Sep 11. doi: 10.1002/ijc.3267

Peitzsch C, Cojoc M, Hein L, Kurth I, Mäbert K, Trautmann F, Klink B, Schröck E, Wirth MP, Krause M, Stakhovsky EA, Telegeev GD, Novotny V, Toma M, Muders M, Baretton GB, Frame FM, Maitland NJ, Baumann M, Dubrovska A (2016). An epigenetic reprogramming strategy to resensitize radioresistent prostate cancer cells. Cancer Res 76(9):2637-51.

Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Fuessel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schaekel K, Bornhaeuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M (2015) Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology; 4:e1008342.